Background: Epidermal growth factor receptor (EGFR) T790M mutation is the most frequent mechanism of resistance among patients with progression during EGFR-tyrosine kinase inhibitor (TKI) therapy. A third-generation EGFR-TKI, osimertinib, demonstrated durable efficacy with mild adverse events in a phase III trial and is considered a novel standard regimen. The tolerability of osimertinib monotherapy has allowed for the development of a more efficacious combination regimen. Preclinical and clinical study data have suggested that vascular endothelial growth factor inhibition can enhance EGFR-TKI activity with tolerable toxicity. Aims: The aim of the present single-arm, phase Ib study is to assess the tolerability of osimertinib combined with ramucirumab in patients with EGFR-mutated, T790M
Introduction
Patients with advanced nonesmall-cell lung cancer (NSCLC) with an epidermal growth factor receptor (EGFR) mutation will benefit from EGFR-tyrosine kinase inhibitors (TKIs) but will inevitably develop a relapse within 10 to 12 months. [1] [2] [3] Tissue samples collected after relapse have shown that the EGFR T790M mutation is the most common cause of resistance (w50%). 4 Osimertinib is an orally available, irreversible third-generation EGFR-TKI. In a preclinical model, osimertinib demonstrated potent activity to EGFR T790M mutation-positive cells. In addition, the inhibitory effect on EGFR wild-type cells is low. A phase III trial comparing osimertinib with platinum doublet chemotherapy in patients with EGFR-TKI resistant, T790M
þ NSCLC (AURA 3
[AZD9291 first time in patients ascending dose study]) was conducted. 5 Regarding the efficacy, the overall response rate (ORR) was 71% in the osimertinib arm and 31% in the chemotherapy arm. Progression-free survival, the primary endpoint, was significantly longer in the osimertinib arm than in chemotherapy arm (median, 10.1 months vs. 4.4 months; hazard ratio, 0.30; P < .001). Adverse events were generally milder in the osimertinib arm. Osimertinib monotherapy is therefore considered a novel standard regimen. However, the tolerability of osimertinib will allow for the development of a more efficacious combination regimen. Ramucirumab is a recombinant human monoclonal antibody that specifically binds to the extracellular domain of vascular endothelial growth factor receptor 2. Efficacy has been confirmed for NSCLC, colorectal cancer, and gastric cancer. The common adverse events of ramucirumab are hypertension, proteinuria, and hemorrhage; all known as VEGF inhibitor-related toxicities. 
Study Protocol

Objectives
The present study primarily aims to assess the safety of osimertinib combined with ramucirumab for patients with EGFRmutated, T790M þ who developed progression during EGFR-TKI therapy.
Study Design
The present study is a single-arm prospective, phase Ib study. The study details have been summarized in Figure 1 .
Endpoints
The primary endpoint is to assess the safety of osimertinib plus ramucirumab at a fixed dose. Dose-limiting toxicity (DLT) will be evaluated during 2 cycles of study treatment. DLT is defined hematologic toxicity, including as anemia (grade 4), thrombocytopenia (grade 3), neutropenia (grade 4) lasting 8 days, febrile neutropenia (grade 3), skin rash (grade 4), proteinuria (3 g/d), or hypertension (grade 4) and nonhematologic toxicity (grade 3) other than electrolyte abnormality.
The secondary endpoints are the ORR, progression-free survival, time to treatment failure, overall survival, and safety during the entire study treatment period.
Eligibility Criteria
The inclusion criteria are as follows: Osimertinib 
Treatment
Treatment will consist of osimertinib plus ramucirumab. An oral dose of osimertinib 80 mg will be administered daily beginning on day 1 and continuing until disease progression. Ramucirumab 10 mg/kg will be administered every 2 weeks beginning on day 1 and continuing until disease progression.
Follow-up and Assessment
To assess efficacy, chest computed tomography scans will be taken every 8 weeks until 72 weeks and every 12 weeks thereafter. Gadolinium-enhanced magnetic resonance imaging of the brain will be performed at baseline before registration for all patients. Adverse events will be graded using the Common Terminology Criteria for Adverse Events, version 4.0.
Statistical Analysis
The present study is designed as a fixed-dose, phase Ib study; thus, the number of participants was not determined using statistical considerations. Six patients who are assessable for DLT will be recruited for the present study. Patients who have either completed 2 cycles of treatment or discontinued study treatment before 2 cycles because of a DLT will be considered evaluable for DLT. If the proportion of participants who experienced a DLT is < 33% during the first 2 treatment cycles, the treatment regimen will be judged as tolerable. If the proportion of participants who experienced a DLT is 33% during the first 2 treatment cycles, this treatment regimen will be judged as intolerable.
Biomarker Analysis
We plan a comprehensive molecular analysis using droplet digital polymerase chain reaction and next generation sequencing. Tumor tissue will be collected at baseline and at disease progression. In addition, 20 mL of peripheral blood will be sequentially collected at baseline and at 2, 4, 8, and 24 weeks, and at disease progression (Figure 1 ).
Ethical Considerations
The study will be conducted in compliance with the principles of the Declaration of Helsinki. The institutional review board of each participating institution approved the study protocol. All the patients will have provided written informed consent before any screening or inclusion procedure is performed. This protocol was registered in the University Hospital Medical Information Network, Japan (protocol identification no. UMIN000030142).
Discussion and Conclusion
To enhance the efficacy of EGFR-TKI monotherapy, combination therapies are under investigation in several clinical trials. Osimertinib combined with ramucirumab is a promising regimen to be tested. To evaluate safety, a phase I study will usually adopt doseescalation cohorts (ie, the conventional 3þ3 method or the continual reassessment method). However, previous study of erlotinib plus bevacizumab showed a tolerable safety profile. Pivotal trials have demonstrated that the adverse events with osimertinib are milder than those with erlotinib. Thus, we determined that osimertinib plus ramucirumab could each be initiated at the full dose level. A similar phase Ib study of this combination regimen has been conducted, mainly in the United States. 7 In that study, 25 patients received osimertinib plus ramucirumab, and a severe adverse event was observed in 1 patient (congestive heart failure). Regarding efficacy, the preliminary ORR was 68% in that study. In EGFR-mutated NSCLC cases, changes in the genetic alterations during combination treatment have not been investigated. As an exploratory analysis, we plan to collect plasma samples sequentially. Using highly sensitive next generation sequencing, we will monitor the changes in the molecular abnormalities.
